CStone Pharmaceuticals Advances Clinical Trial for Innovative Cancer Therapy

CStone Pharmaceuticals ( (HK:2616) ) has issued an update.

CStone Pharmaceuticals announced the submission of a Phase Ib clinical trial application in Australia for CS5001, a ROR1-targeting antibody-drug conjugate, in combination with first-line standard-of-care for diffuse large B-cell lymphoma (DLBCL). This trial aims to expand the therapeutic potential of CS5001 across all DLBCL stages and solid tumors, potentially reshaping the standard-of-care landscape. The global multi-center trial is actively enrolling patients, with promising data indicating significant clinical benefits for DLBCL patients and potential expansion into a Phase II study. CS5001 has shown encouraging safety and anti-tumor activity in preclinical models, with a favorable safety profile and potential for precision treatment in both hematologic and solid tumors.

More about CStone Pharmaceuticals

CStone Pharmaceuticals, established in 2015, is a biopharmaceutical company focused on developing anti-cancer therapies. The company is dedicated to addressing unmet medical needs in China and globally, having launched four innovative drugs and secured approvals for 16 new drug applications across nine indications.

YTD Price Performance: 36.52%

Average Trading Volume: 3,764,938

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$3.96B

Learn more about 2616 stock on TipRanks’ Stock Analysis page.